Here's an analysis of cannabis use in Multiple Sclerosis (MS), based on the provided information and current research.
πΏ Cannabis & MS: Evidence and Applications
π¬ Scientific Evidence
Pain & Spasticity: A 2024 review indicates that Nabiximols, a 1:1 THC:CBD spray, can reduce spasticity by 30-40%.[1]
According to www.iAsk.Ai - Ask AI:
π Emerging Research
Cannabinoids are showing promise in modulating the inflammatory response. Research suggests that they can downregulate pro-inflammatory cytokines such as IL-17 and TNF-Ξ±.[1] A 5-year cohort study from 2025 found no evidence of cognitive decline or addiction risk when using therapeutic doses of cannabis. Furthermore, CBD is believed to ease neuropathic pain by modulating TRPV1 receptors.[1]
Neuroprotection: Animal studies conducted between 2023 and 2025 suggest that combinations of THC and CBD can help preserve myelin and reduce neuroinflammation.[1]
Cognitive & Mood Benefits: A 2024 study revealed that low-dose THC improved processing speed in 60% of MS patients.[1] Additionally, a 2023 trial showed that CBD could lower anxiety and depression scores.[1] A 2025 study also indicated that cannabis improved REM sleep by 20%.[1]
The most relevant answer part is that a 2024 review indicates that Nabiximols, a 1:1 THC:CBD spray, can reduce spasticity by 30-40%.
Sign up for free to save this answer and access it later
Sign up β